Namely, renin angiotensin aldosterone system (RAAS) inhibitors, sodium glucose transporter 2 (SGLT2) inhibitors, erythropoiesis stimulating agents (ESAs), intestinal phosphate binders and vitamin D derivatives are currently included in the pharmacological treatment of CKD patients. Here, SLC5A2 is linked to chronic kidney disease.